Background: Systemic lupus erythematosis (SLE) is a disorder with multiple organ involvement. Haematological abnormalities have been addressed in it, but acquired von Willebrand syndrome is a rarer phenomenon in current disease. The Case: We report acquired von Willebrand syndrome and SLE in a man with brown rash on face, gingival bleeding, easy bruising and epistaxis and laboratory finding of decreased complement, high level of anti-nuclear antibody and anti-DNA. These findings confirmed the diagnosis of SLE. He underwent kidney biopsy and experienced severe pain at the site of biopsy, but the ultra-sonography evaluation showed small sub capsular haematoma at the site of biopsy. During the next 48 hours, gradually APTT prolongation was continued and haematocrit dropped. In spite of FFP infusion and taking tranexamic acid every eight hours, there wasn’t any improvement in haemostatic condition. He received Methylprednisolone and Cyclophosphamid pulses. The patient underwent surgery to roll out vascular complication, but there wasn’t any vascular problem. On the third day, recombinant activated factor VII was infused every two hours until oozing was stopped.
 J. F. Viallard, J. L. Pellegrin, C. Vergnes, A. Borel-Derlon, G. Clofent-Sanchez and A. T. Nurden, “Three Cases of Acquired von Willebrand Disease Associated with Systemic Lupus Erythematosus,” British Journal of Haematology, Vol. 105, No. 2, 1999, pp. 532-537.
 H. Mohri, “Acquired von Willebrand Syndrome: Features and Management,” American Journal of Hematology, Vol. 81, No. 8, 2006, pp. 616-623.
 J. J. Michiels, W. Schroyens, M. van der Planken and Z. Berneman, “Acquired von Willebrand Syndrome in Systemic Lupus Erythematosus,” Clinical and Applied Thrombosis and Hemostasis, Vol. 7, No. 2, 2001, pp. 106-112. http://dx.doi.org/10.1177/107602960100700205
 M. R. Rinder, R. E. Richard and H. M. Rinder, “Acquired von Willebrand Disease: A Concise Review,” American Journal of Hematology, Vol. 54, No. 2, 1997, pp. 139-145.
 H. Mohri, “Acquired von Willebrand Syndrome: Its Pathophysiology, Laboratory Features and Management,” Journal of Thrombosis and Thrombolysis, Vol. 15, No. 3, 2003, pp. 141-149.
 P. W. Friederich, P. C. Wever, E. Briet, C. J. Doorenbos and M. Levi, “Successful Treatment with Recombinant Factor VIIa of Therapy-Resistant Severe Bleeding in Patient with Acquired von Willebrand Disease,” American Journal of Hematology, Vol. 66, No. 4, 2001, pp. 292-294. http://dx.doi.org/10.1002/ajh.1060
 L. E. Silberstein, J. Abrahm and S. J. Shattil, “The Efficacy of Intensive Plasma Exchange in Acquired von Willebrand,s Disease,” Transfusion, Vol. 27, No. 3, 1987, pp. 234-237.
 A. K. Stewart and M. F. Glynn, “Acquired von Willebrand’s Disease Associated with Free Lambda Light Chain Monoclonal Gammopathy, Normal Bleeding Time and Response to Prednisone,” Postgraduate Medical Journal, Vol. 66, No. 777, 1990, pp. 560-562.
 J. C. J. Eikenboom, F. J. M. van der Meer and E. Briet, “Acquired von Willebrand’s Disease Due to Excessive Fibrinolysis,” British Journal of Haematology, Vol. 81, No. 4, 1992, pp. 618-620.
 M. Niiya, K. Niiya, Y. Takazawa, Y. Hayashi, M. Y. Tanio, M. Kushiro, M. Tanimizu, H. Hasegawa and M. Tanimoto, “Acquired Type 3-Like von Willebrand Syndrome Preceded Full-Blown Systemic Lupus Erythematosus,” Blood Coagulation and Fibrinolysis, Vol. 13, No. 4, 2002, pp. 361-365.
 A. Casonato, E. Pontara, A. Doria, A. Bertomoro, M. G. Cattini, P. F. Gambari and A. Girolami, “Lack of Multimer Organization of von Willebrand Factor in an Acquired von Willebrand Syndrome,” British Journal of Haematology, Vol. 116, No. 4, 2002, pp. 899-904.
 S. Hong, J. Lee, H. Chi H, C. Lee, S. Nah, Y. G. Kim, J. S. Oh, H. B. Moon and B. Yoo, “Systemic Lupus Erythematosus Complicated by Acquired von Willebrand’s Syndrome,” Lupus, Vol. 17, No. 9, 2008, pp. 846-848.